HIV Scientific Papers
Achieving virological control in pan-resistant HIV-1 infection: A case series
2022
Diana Canetti, Camilla Muccini, Vincenzo Spagnuolo, Laura Galli, Andrea Poli, Nicola Gianotti, Marcello Feasi, and Antonella Castagna,
The Lancet Vol 77 Month March, 2022 11
IV Push Administration of Ibalizumab: Pharmacokinetics, Safety, and Efficacy
2022
Edwin DeJesus, Gary Richmond, Mezgebe Berhe, Anthony Mills, Tanya Schreibman, Charlotte-Paige Rolle, Kuei-Ling Kuo, Mohammed Zogheib, Olivia G. Goss, R. Brandon Cash, YingAn Lai, Martin Markowitz, Pedro M. Mesquita
HIV-1 Non-Group M Phenotypic Susceptibility to Ibalizumab
2022
L. Poisson-Arnaud, Quentin le Hingrat, JC Plantier and E Alessandri-Gradt
Efficacy, pharmacokinetics, and safety over 48 weeks with ibalizumab-based therapy in treatment-experienced adults infected with HIV-1: a phase 2a study.
2021
J Acquir Immune Defic Syndr.
Gathe JC, Hardwicke RL, Garcia F, et al.
86(4):482-489.
Assessment of genotypic patterns associated with HIV-1 sensitivity to ibalizumab [abstract].
2020
Reviews in Antiviral Therapy & Infectious Diseases.
Jullien H, Leonard M, Cash RB, et al.
7:27. Proceedings of the European Meeting on HIV & Hepatitis 2020.